Vor Bio spikes as J.P. Morgan starts at Overweight on lead asset
Seeking Alpha News (Tue, 9-Dec 10:53 AM ET)
TipRanks (Tue, 9-Dec 9:25 AM ET)
Vor Biopharma Approves Stock Option Repricing Plan
TipRanks (Tue, 9-Dec 8:17 AM ET)
Vor Bio Reports Third Quarter 2025 Financial Results and Provides Corporate Update
Globe Newswire (Thu, 13-Nov 4:01 PM ET)
Vor Bio Launches $100 Million Public Offering—A Strategic Step to Advance Phase 3 Clinical Trials
Market Chameleon (Tue, 11-Nov 4:10 AM ET)
Vor Bio Announces Pricing of Public Offering of $100 Million of Common Stock
Globe Newswire (Mon, 10-Nov 9:56 PM ET)
Vor Bio Announces Proposed Public Offering of $100 Million of Common Stock
Globe Newswire (Mon, 10-Nov 4:01 PM ET)
Globe Newswire (Sat, 8-Nov 11:45 AM ET)
Vor Bio to Participate in Upcoming Investor Conferences
Globe Newswire (Fri, 7-Nov 8:00 AM ET)
Vor Bio Appoints Jeremy Sokolove, M.D. as Chief Medical Officer
Globe Newswire (Mon, 3-Nov 8:00 AM ET)
Vor Biopharma Inc is a clinical stage cell therapy company. It combines a novel patient engineering approach with targeted therapies to provide a solution for patients suffering from hematological malignancies. The company's products include VCAR33, Tremcel and Myelodysplastic Syndrome, Trem-cel+VCAR33 Treatment System, VADC45, CD123, CLL1, EMR2.
Vor Biopharma trades on the NASDAQ stock market under the symbol VOR.
As of December 9, 2025, VOR stock price climbed to $10.72 with 24,489,021 million shares trading.
VOR has a beta of 4.63, meaning it tends to be more sensitive to market movements. VOR has a correlation of 0.10 to the broad based SPY ETF.
VOR has a market cap of $234.88 million. This is considered a Small Cap stock.
In the last 3 years, VOR traded as high as $151.40 and as low as $2.62.
The top ETF exchange traded funds that VOR belongs to (by Net Assets): VTI, VXF, AVSC, DFSU, BMED.
VOR has underperformed the market in the last year with a return of -34.6%, while the SPY ETF gained +13.6%. In the last 3 month period, VOR fell short of the market, returning -72.9%, while SPY returned +5.6%. However, in the most recent 2 weeks VOR has outperformed the stock market by returning +28.2%, while SPY returned +2.1%.
VOR support price is $7.57 and resistance is $9.15 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that VOR shares will trade within this expected range on the day.